Cost-effectiveness analysis of essential hypertension therapy by metoprolol based on gene targeting
- VernacularTitle:基因导向美托洛尔治疗高血压的成本-效果评估
- Author:
Haiqiang SANG
;
Hong YUAN
;
Zhijun HUANG
;
Ming SUN
- Publication Type:Journal Article
- Keywords:
hypertension;
gene polymorphism;
cost-effectiveness analysis;
individual treatment
- From:
Chinese Journal of Practical Internal Medicine
2003;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical effectiveness,safety,cost-effectiveness of Targeting Gene Therapy with conventional therapy on patients with Essential Hypertension by metoprolol.Methods 300 cases of patients with Essential Hypertension were included.165 cases were chosen and assigned to conventional therapy group(Group A)at random.The subjects of Group A were administrated with metoprolol for 100 mg,twice per day.Polymorphism of CYP2D6 and ?1 adenoreceptor gene of the remain 135 subjects were detected,133 cases with of ?1-AR gene carrying Arg 389 allele were devided into three groups according to CYP2D6 genetype:the poor metabolism group(PM,43 cases),intermediate metabolism group(IM,54 cases)and extensive metabolism group(EM,36 cases).The subjects of PM,IM and EM were administrated with metoprolol for 25,100,200 mg/d respectively,twice per day.Blood pressures and side effects were observed during 8-week following-up.The health economic evaluation on Gene Targeting Therapy was determined by using the cost-effectiveness analysis.Results Total effective rate in Group PM,IM or EM were obviously higher than that in Group A(P
